Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 4
2006 3
2008 5
2009 5
2010 3
2011 6
2012 1
2013 5
2014 3
2015 7
2016 7
2017 6
2018 8
2019 3
2020 6
2021 11
2022 7
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium.
Visser MM, Van Muylder A, Charleer S, Isitt JJ, Roze S, De Block C, Maes T, Vanhaverbeke G, Nobels F, Keymeulen B, Mathieu C, Luyten J, Gillard P, Verhaeghe N. Visser MM, et al. Among authors: keymeulen b. Diabetologia. 2024 Apr;67(4):650-662. doi: 10.1007/s00125-023-06084-2. Epub 2024 Jan 18. Diabetologia. 2024. PMID: 38236409
Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes.
Desouter AK, Keymeulen B, Demeester S, Van de Velde U, De Pauw P, Van Dalem A, Lapauw B, De Block C, Gillard P, Pipeleers DG, Gorus FK. Desouter AK, et al. Among authors: keymeulen b. Diabetes Res Clin Pract. 2023 Nov;205:110974. doi: 10.1016/j.diabres.2023.110974. Epub 2023 Oct 25. Diabetes Res Clin Pract. 2023. PMID: 37884063 Free article.
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC; PROTECT Study Investigators. Ramos EL, et al. N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18. N Engl J Med. 2023. PMID: 37861217 Clinical Trial.
Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.
Sordi V, Monti P, Lampasona V, Melzi R, Pellegrini S, Keymeulen B, Gillard P, Linn T, Bosi E, Rose L, Pozzilli P, Giorgino F, Cossu E, Piemonti L. Sordi V, et al. Among authors: keymeulen b. Front Endocrinol (Lausanne). 2023 Jun 20;14:1175640. doi: 10.3389/fendo.2023.1175640. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37409229 Free PMC article. Clinical Trial.
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes.
Van Rampelbergh J, Achenbach P, Leslie RD, Ali MA, Dayan C, Keymeulen B, Owen KR, Kindermans M, Parmentier F, Carlier V, Ahangarani RR, Gebruers E, Bovy N, Vanderelst L, Van Mechelen M, Vandepapelière P, Boitard C. Van Rampelbergh J, et al. Among authors: keymeulen b. BMC Med. 2023 May 24;21(1):190. doi: 10.1186/s12916-023-02900-z. BMC Med. 2023. PMID: 37226224 Free PMC article. Clinical Trial.
Comparison of Omentum and Subcutis as Implant Sites for Device-Encapsulated Human iPSC-Derived Pancreatic Endoderm in Nude Rats.
Nijns JR, De Mesmaeker I, Suenens KG, Stangé GM, De Groot K, Marques de Lima M, Kraus MRC, Keymeulen B, Waelput W, Jacobs-Tulleneers Thevissen D, Pipeleers DG. Nijns JR, et al. Among authors: keymeulen b. Cell Transplant. 2023 Jan-Dec;32:9636897231167323. doi: 10.1177/09636897231167323. Cell Transplant. 2023. PMID: 37129266 Free PMC article.
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial.
Visser MM, Charleer S, Fieuws S, De Block C, Hilbrands R, Van Huffel L, Maes T, Vanhaverbeke G, Dirinck E, Myngheer N, Vercammen C, Nobels F, Keymeulen B, Mathieu C, Gillard P. Visser MM, et al. Among authors: keymeulen b. Lancet Diabetes Endocrinol. 2023 Feb;11(2):96-108. doi: 10.1016/S2213-8587(22)00352-7. Lancet Diabetes Endocrinol. 2023. PMID: 36702566 Clinical Trial.
CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients.
Vandewalle J, Desouter AK, Van der Auwera BJ, Tenoutasse S, Gillard P, De Block C, Keymeulen B, Gorus FK, Van de Casteele M; Belgian Diabetes Registry. Vandewalle J, et al. Among authors: keymeulen b. Clin Exp Immunol. 2023 Mar 24;211(3):224-232. doi: 10.1093/cei/uxad002. Clin Exp Immunol. 2023. PMID: 36622793 Free PMC article.
The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.
Visser MM, Charleer S, Fieuws S, De Block C, Hilbrands R, Van Huffel L, Maes T, Vanhaverbeke G, Dirinck E, Myngheer N, Vercammen C, Nobels F, Keymeulen B, Mathieu C, Gillard P. Visser MM, et al. Among authors: keymeulen b. J Diabetes Sci Technol. 2024 May;18(3):660-666. doi: 10.1177/19322968221128315. Epub 2022 Sep 29. J Diabetes Sci Technol. 2024. PMID: 36172693 Clinical Trial.
94 results